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The accumulation of intracytoplasmic inclusion bodies (Lewy bodies) composed of aggregates 
of the alpha-synuclein (α-syn) protein is the principal pathological characteristic of Parkinson’s 
disease (PD) and may lead to degeneration of dopaminergic neurons. To date there is no 
medication that can promote the efficient clearance of these pathological aggregates. In this 
study, the effect on α-syn aggregate clearance of ginkgolic acid (GA), a natural compound 
extracted from Ginkgo biloba leaves that inhibits SUMOylation amongst other pathways, was 
assessed in SH-SY5Y neuroblastoma cells and rat primary cortical neurons. Depolarization of 
SH-SY5Y neuroblastoma cells and rat primary cortical neurons with KCl was used to induce α- 
syn aggregate formation. Cells pre-treated with either GA or the related compound, anacardic 
acid, revealed a significant decrease in intracytoplasmic aggregates immunopositive for α-syn 
and SUMO-1. An increased frequency of autophagosomes was also detected with both 
compounds. GA post-treatment 24 hr after depolarization also significantly diminished α-syn 
aggregate bearing cells, indicating the clearance of pre-formed aggregates. Autophagy inhibitors 
blocked GA-dependent clearance of α-syn aggregates, but not increased autophagosome 
frequency. Western analysis revealed that the reduction in α-syn aggregate frequency obtained 
with GA pre-treatment was not accompanied by a significant change in the abundance of SUMO 
conjugates. The current findings show that GA can promote autophagy-dependent clearance of 
α-syn aggregates and may have potential in disease modifying therapy. 
 






Parkinson’s disease (PD) is a multi-system proteinopathy reflecting the progressive loss of 
dopaminergic nigrostriatal neurons causing a variety of motor deficits, including resting tremor, 
muscular rigidity, bradykinesia and postural instability, and non-motor alterations, such as 
hypsomia, autonomic and other dysfunctions (Breydo et al., 2012; Eckermann, 2013; Jellinger, 
2014). The neuropathological hallmark of PD is the widespread occurrence of intracellular 
inclusion bodies (Lewy bodies) and neuritic deposits (Lewy neurites) of phosphorylated - 
synuclein (-syn). Although the formation of Lewy bodies is considered a protective cell 
response, Lewy body maturation eventually becomes toxic triggering neuronal death. The 
pathological accumulation of intracellular -syn aggregates is also linked to a variety of other - 
synucleopathies, including multiple system atrophy (MSA) and dementia with Lewy bodies 
(DLB)(Breydo et al., 2012; Radford et al., 2014; Vijayakumaran et al., 2015). Oxidative / 
nitrosative stress, post-translational modifications, proteolytic stress and calcium dyshomeostasis 
are some major factors leading to the formation of cytotoxic -syn species and neuronal 
degeneration (Nath et al., 2011; Schmid et al., 2013; Wang et al., 2013). Reversal and prevention 
of -syn aggregation may provide cytoprotection in -synucleopathies and there has been 
significant recent interest in approaches to promote aggregate clearance (Jackrel and Shorter, 
2014; Jackson-Lewis et al., 2012; Kalani, 2014; Valera and Masliah, 2013). 
 
Neuropathological -syn inclusion bodies and -syn inclusion bodies formed in cell culture 
experiments accumulate the small ubiquitin-like modifier-1 (SUMO-1) (Pountney et al., 2005; 
Sarge and Park-Sarge, 2011; Weetman et al., 2013; Wong et al., 2013). SUMOylation is 
involved in a variety of different cellular pathways by regulating protein-protein or protein-DNA 
interactions (Krumova et al., 2011; Vijayakumaran et al., 2015, 2018; Henley et al., 2018). As 
with ubiquitination, SUMOylation involves E1 (SUMO-activating), E2 (SUMO-specific 
conjugating, Ubc9) and E3 (SUMO ligase, eg., PIAS3) enzymes (Da Silva-Ferrada et al., 2012; 
Wilkinson et al., 2010). SUMO-1 has been found to associate with cytoplasmic -syn inclusion 
bodies in PD, MSA and DLB and also with intranuclear inclusion bodies such as polyglutamine 
aggregates in Huntington’s disease (HD) (Pountney et al., 2005; Pountney et al., 2003; Rott et 




SUMOylation, neurodegenerative disease pathology and cell responses to misfolding and 
aggregation (Vijayakumaran et al., 2015; 2018; Rott et al., 2017). Wild-type -syn and disease- 
linked mutants have been shown to be SUMO substrates indicating direct modulation of protein 
solubility, whereas links between SUMOylation and autophagy suggest indirect involvement via 
the cellular response to protein aggregate accumulation (Da Silva-Ferrada et al., 2012; Janer et 
al., 2010; Kim et al., 2014; Krumova et al., 2011). Moreover, over-expression of PIAS2, the - 
syn SUMO ligase resulted in increased accumulation of intracellular aggregates of PD-linked - 
syn mutants (Rott et al., 2017). SUMO-1 was also found to be associated with lysosomes 
clustered around or embedded in -syn deposits in pathological specimens and cell culture 
models, where it is conjugated to Hsp90 (Wong et al., 2013). 
 
The removal of aggregating protein including misfolded proteins and defective organelles occurs 
through two main proteolytic pathways; the ubiquitin-proteasome pathway (UPS) and the 
autophagy-lysosomal pathway (ALP). Defects in these pathways prevent the clearance of 
proteins from neuronal and glial cytoplasm, leading to a variety of neurodegenerative disorders. 
Larger protein aggregates as well as damaged organelles are unable to be degraded by the 
proteasome and are cleared through macroautophagy. Macroautophagy, a prominent constituent 
of ALP, is a process that involves the bulk lysosomal degradation of soluble and pathological 
aggregates and damaged organelles (Tanik et al., 2013; Winslow et al., 2010). Defects in ALP 
have been demonstrated to cause neurodegeneration in animal models deficient in autophagy- 
related proteins within neuronal tissues as well as human neurodegenerative lysosomal storage 
diseases (Futerman and van Meer, 2004; Hara et al., 2006; Inoue et al., 2012; Nixon et al., 2008; 
Tanik et al., 2013). 
 
GA and the related molecule anacardic acid (AA) have been shown to inhibit SUMOylation by 
blocking the function of Ubc9 (Fukuda et al., 2009). Previous studies have investigated the 
outcomes of inhibiting the SUMO-pathway using GA, concluding that SUMOylation has a 
cytoprotective role in maintaining cellular health (Guo et al., 2015; Tossidou et al., 2014). GA 
and AA, were investigated to determine the effects on -syn aggregates. GA was found to 
promote clearance of pre-formed -syn aggregates at concentrations that were not cytotoxic and 




current study suggests that GA or analogues could be useful therapeutics against Parkinson’s 
disease. 




SH-SY5Y neuroblastoma cells (ATCC® CRL-2266™) were seeded at 10,000 cells per well in 
24-well plates on 10 mm glass coverslips for immunofluorescence confocal imaging and 
analysis. Cells were incubated for a period of 24 h at 37 °C with 5 % CO2 in 1 mL DMEM/10 % 
FBS with 0.04 % Amphotericin B and 1 % Strep/Penicillin prior to treatment to allow cells to 
adhere. In parallel, cells were seeded and incubated in 6-well plates at 300,000 cells per well for 
cell lysate preparation, SDS-PAGE and Western blotting. 
 
Embryonic cortical neurons were isolated from E18 Wistar Rattus Norvergicus embryos. 
Cortical areas were dissected and trypsinised, before being plated on PLL-coated 25 mm glass 
coverslips. Cells were initially plated in plating medium (Neurobasal media + 10% horse serum, 
B27 supplement, 2 mM Glutamax, 1× penicillin/streptomycin). After 24 hours, the plating 
medium was replaced with feeding medium (Neurobasal media, B27 supplement, 1.2 mM 






For immunofluorescence analysis, cells were pre-treated with medium containing 6M to100 
M GA or AA (Calbiochem, USA) for 1 h. Potassium chloride (50mM) was then added to these 
pre-treated wells and was incubated for 1 h to induce -syn aggregates as described previously 
(Follett et al., 2013; Rcom-H'cheo-Gauthier et al., 2014). Wells were then replenished with fresh 
medium containing GA or AA only for an additional 24 h or 48 h. SH-SY5Y controls of both 
KCl-depolarised and non-depolarised cells were performed. For gel electrophoresis and western 
blotting, the experiment was repeated in 6-well plates pre-treated with medium containing 




For post-treatment with GA, cells were depolarized with KCl for 1 h without inhibitor pre- 
treatment. After 24 h, the medium was removed and replenished with fresh medium containing 
10M, 40M and 80M of GA for an additional 24 h. Cell lysates from 6-well plates were 
prepared for gel electrophoresis and Western blot analysis and immunofluorescence results were 
obtained from coverslips from 24-well plates. After incubation, post-treatment cell viability was 
determined by MTT assays. 
 
In parallel experiments, KCl-depolarised SH-SY5Y cells were incubated for 23 hours for the 
induction of -syn aggregation and were then treated with medium containing the autophagy 
inhibitors, chloroquine and bafilomycin A1, at 40nM and 10M, respectively for 1 hour. The 
medium was then replaced with medium containing 10M GA as well as the autophagy 
inhibitors for an additional 24 hours. 
 





Coverslips were washed briefly in DPBS prior to fixation. Neuroblastoma cells were fixed and 
permeabilized with 3:1 methanol: acetone and blocked with 20% normal horse serum (NHS). 
Primary neurons were fixed in 3.7% v/v paraformaldehyde, 5 % w/v sucrose, PBS (1 h), then 
quenched (10 m) in 0.1 M glycine, then permeabilized in 0.1 % w/v Triton X-100, 10 NHS. The 
following primary antibodies were used for immunostaining: monoclonal mouse anti-α-syn 
antibody (LB509, Invitrogen, 1:100), polyclonal sheep anti-SUMO-1 antibody (Abcam, 
ab22738, 1:100), polyclonal rabbit Cathepsin-D antibody (Abcam, ab826-250, 1:200) and 
polyclonal rabbit anti-LC3 antibody (Abcam, ab128025, 1:200). Alexafluor (AF)-conjugated 
secondary antibodies (Molecular Probes, Invitrogen) AF488 anti-mouse (A21202), AF568 anti- 
sheep (A21099) and AF647 anti-rabbit (A31573) were used for immunofluorescence and 
mounted onto microscope slides using Prolong Gold with DAPI mounting medium (Invitrogen). 




Laser Scanning Confocal Microscopy Image Analysis & Cell Counting 
 
Immuno-labelled slides were imaged using the Olympus Fluoview FV-1000 confocal laser 
scanning microscope. Negative control secondary antibody only slides were imaged to determine 
the appropriate microscope settings (laser high voltage, electronic gain and offset) for subsequent 
image analysis. A 60X oil immersion lens was used for imaging. Imaging of DAPI, Alexa-fluor 
488, and Alexa-fluor 568 were performed in a single scan from the first channel whereas Alexa- 
fluor 647 anti-rabbit was imaged in a single scan from the second channel. The channels were 
then merged, and the images were exported to be edited using the Olympus FV-1000 viewer 
software. Representative images are shown. 
 
Cells immunostained for SUMO-1 (red) and cathepsin-D (green), lysosomal marker, were 
analysed for co-localisation. Quantification was performed by counting lysosomes and 
classifying them as either SUMO-1 positive (yellow), or SUMO-1 negative (red). SUMO-1 
positive lysosomes were calculated for α-syn IB-positive or negative. IB-positive cells were 
classified as bearing distinct bright α-syn puncta as positive aggregates (1m). LC3-positive 
autophagosomes were counted manually as distinct bright puncta. For autophagy inhibitor 
treatments, LC3 puncta were analysed using ImageJ (NIH). Background labelling was excluded 
(0.2%) and LC3 were counted using the Analyse Particles function. Each coverslip had a 
standard pattern of 5 regions of interest (ROI) and experiments were performed in triplicate 
(n=15) with ~40 cells counted per ROI. For post-treated cells, immunostained cells were 
manually counted as IB-positive, bearing large α-syn-positive aggregates (2m) within each 
ROI (n=10). Images were de-identified to avoid bias. Results were analysed as the proportion of 
total cells as DAPI-stained nuclei. 
 
Cell Lysate Preparation 
 
 
Following drug treatments, whole cell protein extracts were prepared using cell lysis buffer 
(RIPA Buffer, Sigma, R0278) supplemented with protease inhibitor cocktail (1% v/v PIC, 
Sigma, P8340) and N-ethylmaleimide (50mM NEM, Sigma, E3876). Cells in each 6-well plate 




rpm for 5 min. The supernatant was discarded, and the pellet was lysed in RIPA buffer 
supplemented with PIC and NEM to obtain cytosolic proteins. Protein quantification was 
performed using the Thermo Scientific BCA Assay kit as per manufacturer’s instructions. Equal 
amounts of sample proteins were diluted in 2x Laemlli buffer containing 5% β-mercaptoethanol 
(1:1, Sigma, S3401). Samples were boiled at 100oC for 8 minutes prior to loading into gel. 
 
 
Gel Preparation and Electrophoresis 
 
 
Samples were subjected to SDS-PAGE using either 10% (SUMO-1) or 12% (LC3) gel densities 
(40% Acrylamide/Bis 29:1, Bio-Rad, CA, USA). Subsequently, proteins were transferred onto 
PVDF membranes (Merck Immobilon-P, 0.45um pore size). Membranes were blocked using 
solutions of either 5% or 3% skim milk and\or bovine serum albumin (BSA) diluted in Tris- 
buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 1 h. Membranes were briefly 
washed with TBS-T, then probed with the specific primary antibodies at the recommended 
dilutions by the manufacturer in TBST-T overnight at 40C with gentle rocking. Primary 
antibodies were: rabbit anti-SUMO-1 (Abcam, ab3819, 1:1000), rabbit anti-Hsp90 (Cell 
Signalling, 4877S, 1:1000), rabbit anti-LC3a/b (Abcam, ab128025, 1:1000) and mouse anti-- 
actin (Abcam, ab8226, 1:1000). Membranes were washed three times for 5 min each and re- 
probed for the appropriate HRP-conjugated secondary antibody (Bio-Rad Goat HRP Conjugates; 
anti-rabbit # 170-6515, anti-mouse #170-6516) suspended in either 5% skim milk or BSA at 
1:3000 under room temperature for 1 h. Membranes were washed (3x 5 minutes) where the 
proteins of interest were detected using the SuperSignal West Femto chemiluminescent substrate 
(Pierce) and visualized using the ChemiDocTMXRS+ System (Bio-Rad). The intensity of each 





All data were analyzed using Graphpad Prism. Standard error of the mean for graphs was 
𝜎 






Ginkgolic acid and anarcadic acid decrease -syn aggregate frequency 
 
To investigate the influence of ginkgolic acid and the structurally-related compound, anacardic 
acid, on -syn aggregates, we utilized a well-established PD cell model. Potassium 
depolarization (1 h) of SH-SY5Y neuroblastoma cells was used to induce a transient increase in 
intracellular free calcium, resulting in frequent, small cytoplasmic -syn puncta after 24 h and 
large, Lewy body-like perinuclear -syn inclusions after 48 h, as described previously (Follett et 
al., 2013; Rcom-H'cheo-Gauthier et al., 2014). Under these conditions, it has been shown 
previously that cytoplasmic inclusion bodies form that are positive for -syn, thioflavin T, 
phosphorylated--syn, LAMP1 and p62 (Follet et al., 2016; Rcom-H'cheo-Gauthier et al. 2017). 
SH-SY5Y cells were pre-treated with AA, GA or sham for 1 h. The cells were subsequently 
depolarized with 50mM KCl for 1 h to raise intracellular free Ca2+ and induce -syn aggregation, 
then incubated for a further 24 h with or without SUMO-1 inhibitors. Previous studies have 
shown that 24 h incubations following 1 h KCl depolarisation of SH-SY5Y cells caused frequent 
-syn-positive aggregates enabling the use of this as a model for PD (Follett et al., 2013; Rcom- 
H'cheo-Gauthier et al., 2014). Frequent -syn puncta were observed in cells treated with 50mM 
KCl for 1 h after incubation for a further 24 h (Figure 1A) as in the previous studies, which also 
showed increased -syn expression (Rcom-H'cheo-Gauthier et al. 2017). Cell counting showed a 
significant increase in the proportion of aggregate-bearing cells (p<0.05) compared to controls 
(Figure 1C, 2E). To determine the influence of GA or AA treatments on the proportion of -syn 
aggregate-positive cells, SH-SY5Y cells were pre-treated with AA or GA before depolarising 
cells with 50mM of KCl. Subsequently, these cells were incubated in the presence of AA or GA 
for 24 h. Immunofluorescence staining showed a decrease in the frequency of -syn puncta in 
cells co-treated with AA or GA compared to control depolarised SH-SY5Y (Figure 1B, 1D). Cell 
counting analysis revealed a significant reduction in the proportion of aggregate-bearing SH- 
SY5Y cells (p<0.01) when treated with AA or GA compared to untreated depolarised cells 
(Figure 1C, 2E). Previous studies have shown that GA treatment can decrease the steady-state 
level of -syn (Rott et al., 2017). However, this is the first demonstration that GA (and AA) can 





Previous studies have revealed increased levels of SUMO-1-positive lysosomes in -syn 
aggregate-bearing cells in MSA brain tissue sections and cell culture models and SUMO-1 
associated with CatD-positive domains in intracytoplasmic -syn inclusion bodies (Wong et al., 
2013). More recently, over-expression of the SUMO ligase, PIAS2, was found to boost 
cytoplasmic -syn aggregates, whilst treatment with the SUMOylation inhibitor, GA, reduced 
steady-state -syn levels (Rott et al., 2017). Immunofluorescence staining showed an increase in 
SUMOylated lysosomes (yellow puncta) indicating colocalization of CatD and SUMO-1 
clustered in a perinuclear location in response to KCl depolarization (Figure 1F, 1G). This is 
consistent with previous studies showing SUMO-1-positive lysosomes cluster around protein 
inclusion bodies (Wong et al., 2013). Cells treated with AA or GA, respectively, showed 
drastically decreased numbers of lysosomes positive for SUMO-1. Cell counting analysis 
revealed a significant decrease in the co-localisation of SUMO-1 to lysosomes with AA 
(p<0.001) or GA (p<0.01) treatments, respectively, compared to untreated depolarized SH-SY5Y 
(Supp. 1A). 
 
We also investigated the effect of GA on primary rat neurons subjected to the same KCl- 
depolarization treatment. Figure 2 A-C shows example images of treatments of 7 DIV primary 
neurons with 0, 25 or 50 mM KCl for 1 h, followed by incubation for 48 h. Treatment with 25 
mM KCl (Figure 3 B) resulted in the redistribution of -syn from cellular processes, becoming 
more focused in the cell body, accompanied by focal perinuclear accumulations of -syn 
(arrows) and enlarged accumulations of -syn along some processes (arrowheads). Treatment 
with 50 mM KCl resulted in an increased frequency of focal -syn aggregates and further 
reduction in -syn in the processes (Figure 2 C). Whilst 7 DIV cultures showed little effect on 
cell morphology from KCl treatment, neuronal cultures treated with KCl at 14 DIV showed 
frequent cell swelling and retraction of processes (data not shown). In parallel experiments 
(Figure 2 D-F), co-treatment with 10 M GA at 7 DIV resulted in reduced MAP-2 marker, -syn 
staining of cell bodies and processes and few focal perinuclear or punctate accumulations in cell 
processes. Due to the diverse population of neurons present and extensive overlap of the cellular 






Ginkgolic acid and anacardic acid have little effect on SUMOylation 
 
Western analysis was used to determine the total levels of protein SUMOylation in parallel 
experiments. Total band integrals showed a significant increase in SUMO-1 conjugates for 
depolarised SH-SY5Y compared to non-depolarised SHSY5Y (p<0.05) for the 90 KDa band, but 
no significant change for major bands at 80, 75, 30, 20 or 15 KDa, the latter band being 
attributed to SUMO-1 monomer. Western analysis of the SUMO-1 90kDa band showed a 
significant decrease at 40M (p<0.05) or 80M (p<0.01) GA for depolarized cells, but no 
significant change in the other major bands (Figure 3B). Previous immunocapture and reverse 
immunocapture studies on isolated lysosomes and purified human pathological -syn inclusions 
bodies have revealed SUMO-1 conjugated to Hsp90 (Wong et al. 2013). The expression of 
Hsp90 was increased in KCl depolarized cells and treatment with 80M GA resulted in a 
significant reduction in expression in the KCl depolarized cells (Fig. 3 C & D). 
 
To determine the influence of GA under prolonged treatment, experiments were conducted for a 
period of 48 h both with and without depolarization. There was a substantial reduction of 
SUMO-1 bands at 100M inhibitor in both control and KCl-treated cells (Supp. 1B). This is 
consistent with previous studies of GA cell culture treatments (Rott et al., 2017). 
 
Ginkgolic acid and anacardic acid upregulate macroautophagy 
 
 
In order to investigate the influence of GA and AA on macroautophagy, we investigated the 
cellular levels of autophagosomes utilizing the autophagosomal marker, LC3. As illustrated in 
Figure 4A and 4C, the frequency of LC3-positive puncta was found to be upregulated with 
10M AA or GA treatments in depolarized SH-SY5Y. Cell counting analysis of LC3-positive 
puncta (mean LC3 puncta per ROI) revealed a significant increase in cellular levels of LC3- 
positive autophagosomes in depolarized and non-depolarized cells (p<0.05) treated with 10M 




Western analysis showed increased intensity of the LC3b band at 10kDa, indicating increased 
macroautophagy, in KCl-depolarized SH-SY5Y cells and non-depolarized cells with increasing 
concentrations of GA (Figure 4E). Western blot integration revealed a significant increase in the 
LC3b band in depolarized SH-SY5Y at 40M (p<0.05) and 80M (p<0.01) GA treatments and a 
significant upregulation of the LC3b band at 80M (p<0.01) GA treatments in non-depolarized 
SH-SY5Y cells (Figure 4F). We therefore confirmed by both imaging and Western analysis that 
macroautophagosomes are increased in GA and AA treated cells, especially after KCl 
depolarization. 
 
In parallel experiments, analysis of LC3-positive puncta in 7 DIV primary rat cortical neurons 
subjected to treatment with 10M GA showed increased numbers of LC3-positive 
autophagosomes (arrowheads) in both the processes and cell bodies of 49 ± 5 in KCl 
depolarized, 24 ± 4 in non-depolarized compared to 8 ± 2 in untreated (Figure 4G). 
 
Post treatment with GA reduces the frequency of -syn aggregates 
 
We were interested to determine if GA post treatment could promote the clearance of pre-formed 
-syn aggregates. To determine if post-treatment with GA influences the frequency of -syn 
aggregates, parallel experiments were conducted where the frequency of -syn-aggregate 
positive cells was evaluated using immunofluorescence. Figure 5A illustrates the formation of 
large Lewy body-like structures staining for -syn in depolarised SH-SY5Y with a 48 h post- 
depolarization incubation period with no GA treatment. The larger aggregates observed after 48 
hr post-depolarization are consistent with previous studies (Follett et al., 2013). The inclusion 
bodies formed in KCl-depolarized SH-SY5Y cells have been shown previously to stain 
positively for LB markers, thioflavin T, phosphorylated--syn, LAMP1 and p62 (Follet et al., 
2016; Rcom-H'cheo-Gauthier et al. 2017). SUMO-1 puncta were clustered around -syn 
aggregates as in previous experiments with 1321N1 cells (Wong et al., 3013). In parallel, SH- 
SY5Y cells were post treated at 24 h after depolarization with GA at 10M, 40M and 80M 
concentrations, then incubated for a further 24 h with GA present. The frequency of -syn- 




formed aggregates (Figure 5B). A few large and several small aggregates were observed with 
10M GA post-treatments, a few small aggregates were observed with 40M GA and almost no 
aggregates were detected at 80M GA (Figure 5B). Cell counting analysis of large (2m) - 
syn-positive aggregate-bearing SH-SY5Y cells showed a significant decrease in cells bearing - 
syn positive IB in depolarised cells when treated with increasing concentrations of GA at 10M, 
40M and 80M (p<0.0001) (Figure 5C). There were no large aggregates found in non- 
depolarised SH-SY5Y. At 48 h post depolarization, SH-SY5Y cells showed no significant 
difference in viability by MTT assay, compared to non-depolarized cells (Figure 5 D). The 
addition of 10M GA at 24 h had no effect on viability. However, at 40M and 80M GA, there 
was a significant increase (p<0.001) in viability in depolarized, compared to control, with 80M 
GA resulting in a 20% reduction in viability in non-depolarized, compared to control ((p<0.05). 
 
Post treatment with GA has little effect on SUMOylation 
 
 
In order to evaluate the SUMOylation level in cells post-treated with GA at increasing 
concentrations, we first allowed potassium depolarized SH-SY5Y cells to incubate for 24h to 
induce -syn-positive aggregates within cells and subsequently treated cells with increasing 
concentrations of 10M, 40M and 80M GA for an additional 24 h (Figure 6A). Figure 6B 
illustrates the comparison of the SUMO-1 90 KDa band, showing that for 10 M (p<0.05), 
40M (p<0.05) and 80M (p<0.01) GA treatments, integration of cellular levels of the 90kDa 
SUMO-1 band were significantly reduced compared to no SUMO-1 inhibition in depolarized 
SH-SY5Y cells (Figure 6B). We observed no significant difference in this band at 10 M GA in 
the pre-treatment experiments. None of the other major SUMO-1 conjugates was significantly 
different. Western analysis of Hsp90 similarly revealed a decrease in the depolarized cells at 
40M (p<0.05) and 80M (p<0.05) GA treatments (Figure 6C, D). 
 
Post treatment with GA upregulates macroautophagy 
 
 
Parallel experiments were conducted to evaluate the cellular levels of LC3-positive 




increasing concentrations. Figure 7A represents images of SH-SY5Y cells stained for LC3 (red). 
When compared to depolarised cells without GA treatment, depolarised cells subjected to 10M 
GA showed a distinct upregulation of LC3-positive puncta (Figure 7A). Western analysis of cell 
lysates subjected to post GA treatment showed a prominent upregulation of the LC3b band, 
particularly at 80M GA, as seen in Figure 7B. Band integration showed that LC3b was 








In order to determine if the GA-mediated clearance of -syn aggregates in KCl-depolarized SH- 
SY5Y cells is dependent on lysosomal activity, we conducted a series of parallel experiments 
where cells were first subjected to depolarization with 50 mM KCl, then incubated for 23 hours 
to form aggregates. Cells were then incubated for 1 hour with either chloroquine or bafilomycin 
A1, to block autophagy, or vehicle then were treated with 10 µM GA in the presence of the 
autophagy inhibitors for a further 24 hr. Immunofluorescence analysis revealed that there was no 
significant difference in the proportion of -syn aggregate bearing cells in cells that received 
either of the autophagy inhibitor treatments in addition to GA, compared to KCl only, whereas, 
the control experiments showed a significant reduction in aggregates with GA treatment in 
comparison both to no GA (p<0.001), or GA plus either chloroquine or bafilomycin A1 
(p<0.05)(Figure 8 A – F). Conversely, analysis of the frequency of LC3-positive puncta (Figure 
8 G - L) showed that combined GA and autophagy inhibitor treatment each resulted in 
significantly increased LC3-positive autophagosomes per cell compared to non-depolarized or 








The current study incorporated the use of an -syn aggregation cell model of PD, whereby KCl 
was used to induce membrane depolarization in SH-SY5Y neuroblastoma cells or rat cortical 
neurons, leading to formation of frequent microscopically-visible -syn aggregates over the 
subsequent 24-48 hrs. GA and AA that both have inhibitory activity towards the ubc9-enzyme in 
the SUMO pathway were utilized to determine their influence on the accumulation of -syn 
aggregates after 24 hr incubations with the inhibitors. GA in particular was found to result in 
reduced -syn aggregates and increased macroautophagy markers and was able to promote the 
clearance of pre-formed -syn aggregates. 
 
In previous studies, it was determined that SUMO-1 marks a subset of lysosomes that cluster 
around pathological -syn inclusion bodies and tau deposits in MSA and progressive 
supranuclear palsy (PSP) brain tissue, respectively (Wong et al., 2013). Hsp90 has been 
identified to be associated with SUMO-1 in pathological intra-nuclear inclusion bodies 
(Pountney et al., 2008) and glial -syn aggregates (Wong et al., 2013). SUMOylation of Hsp90 
has also been shown to modulate the interaction with the Aha1 co-chaperone (Mollapour et al., 
2014). Thus, SUMO-1 modification of hsp90 may be linked to the molecular cascade of the 
autophagy lysosome system when cells respond to an accumulation of aggregates that cause 
neurodegeneration. SUMOylation was also upregulated in the lesioned hemisphere of a unilateral 
rotenone lesion model of PD (Weetman et al., 2013). We hypothesized that inhibiting protein 
SUMOylation using SUMO E1-enzyme (Ubc9) inhibitors to partially inhibit SUMOylation may 
influence the autophagy lysosome system and affect the turnover of -syn aggregates in a 
cellular PD model. However, although GA was confirmed to cause significant inhibition of 
SUMOylation at 100 M as established in earlier studies, at the 10M concentration that 
effectively promoted -syn aggregate clearance, there was very little influence on the expression 
of SUMO-conjugates. Only the 90 KDa SUMO band associated with the occurrence of -syn 
aggregates was affected at this concentration of GA. Other mechanisms may therefore come into 
play to mediate GA-dependent aggregate clearance. For example, GA has been shown to 




of 3M GA (Maleeva et al., 2015). GA has also been shown to inhibit fatty acid synthase and 
HIV protease, modulate Bcl-2/Bax apoptosis effectors and inhibit various phosphatases, 
including in the STAT3 signalling pathway, although most of these activities are in the 100 M 
or more range. 
 
SUMOylation of lysosomes and SUMO-1 staining of aggregates was increased in response to - 
syn aggregation in the SH-SY5Y cell model. We found that GA and AA resulted in reduced 
frequencies of SUMO-positive perinuclear puncta and SUMO-1-positive lysosomes. GA and 
AA upregulated LC3-positive autophagosomes and reduced the frequency of intracellular -syn- 
positive inclusion bodies in potassium depolarized SH-SY5Y neuroblastoma cells. Similar 
results were also obtained in 7 DIV primary rat cortical neurons. Similar to the results obtained 
in previous studies (Wong et al., 2013), SUMO-1 was found to be co-localised with the 
cathepsin-D (CATD) lysosomal marker in aggregate positive cells. Using low doses of AA or 
GA (10M), SUMO-1 colocalization with CatD-positive lysosomes in IB-positive cells were 
significantly reduced. Western analysis for SUMO-1 showed that GA caused a slight reduction 
only in the 90 KDa SUMO-1 band, whilst other major SUMO-1 conjugates were unaffected at 
this low concentration of GA. Whilst 10M GA had little effect on total SUMO-1 conjugates, 
there was a four-fold reduction of SUMO-1 associated with lysosomes, suggesting a greater 
sensitivity of the lysosomal SUMO-conjugates to GA treatment. As SUMO-positive lysosomes 
have been shown to be associated with -syn (and polyglutamine) aggregates under a variety of 
conditions in previous cell culture experiments (Wong et al., 2013), this effect may be associated 
with the clearance of -syn aggregates, although we cannot exclude a direct effect on 
SUMOylation. This low dose of GA also showed no significant cytotoxicity. Whereas, cells 
subjected to 100M GA showed 80-90% loss of SUMO-1 conjugates and 80M GA resulted in 
20 % decreased viability in non-depolarized cells, consistent with toxicity. The combination of 
GA and depolarization increased viability which is difficult to interpret, but may be due to 
effects on cell signalling. 
 
In our autophagy inhibitor treatment experiments, treatment with chloroquine inhibits autophagic 
flux by decreasing autophagosome-lysosome fusion (Mauthe et al., 2018). Therefore, increased 




but did not result in productive autophagy and subsequent clearance of -syn aggregates. 
Similarly, the vesicular ATPase (V-ATPase) inhibitor, bafilomycin A1, disrupts autophagic flux 
by inhibiting V-ATPase-dependent lysosome acidification and autophagosome-lysosome fusion 
(Mauzevin and Neufeld, 2015). Our studies therefore suggest that GA-mediated clearance of - 
syn aggregates requires active macroautophagy and the fusion of autophagic vesicles with 
lysosomes. 
 
Reports have suggested that SUMOylation of substrate proteins may have an endogenous 
neuroprotective response. It has been shown that the overexpression of SUMO increases cell 
survival under oxygen and glucose deprivation whereby the knockdown of SUMO proved to be 
deleterious. Conversely, down regulating SUMOylation of proteins in diseases characterised by 
hyper SUMOylation is also beneficial. (Cimarosti et al., 2012; Datwyler et al., 2011; Guo et al., 
2015; Silveirinha et al., 2013; Wilkinson et al., 2010). An in vitro study also revealed the 
neuroprotective role of SUMO in that the SUMOylation of a small portion of -syn was able to 
prevent its aggregation (Abeywardana and Pratt, 2015). Consistent with that finding, a cell 
culture study showed that SUMO-deficient -syn presented with exacerbated aggregation 
causing cellular toxicity (Krumova et al., 2011). More recently, the SUMO ligase PIAS2 was 
found to directly SUMOylate -syn and overexpression of PIAS2 could increase intracellular 
aggregates of -syn PD-linked mutants (Rott et al., 2017). Moreover, GA treatment of HEK293 
cells over-expressing -syn or primary rat neurons reduced the steady-state level of wild-type - 
syn (Rott et al., 2017). 
 
It has been suggested that SUMOylation of lysosomal Hsp90 may be important for its function in 
CMA (Vijayakumaran et al., 2015, 2018). Previous studies have evaluated the SUMO-1 labelling 
of lysosomes in cells treated with proteasome inhibitor, MG132, showing an increase in the 
90kDa SUMO-1-positive band that was immunopositive for Hsp90 and identifying via 
immunocapture the lysosomal SUMO-conjugate of Hsp90 that was also present in purified 
human pathological -syn aggregates (Wong et al., 2013). In the current study, the SUMO-1 
positive band at 90kDa showed significant decrease at increasing concentrations of GA in 
depolarized cells. The same SUMO-1-positive 90 KDa band was also increased in the 




time that cells are responding to aggregate burden, the selective effects on the 90 KDa band may 
indicate that there is little influence on the equilibrium levels of other SUMO conjugates over the 
24 hr timescale of GA treatment. It has been shown previously that inhibition of Hsp90 induces 
macroautophagy and reduces the aggregation of -syn (Chaari et al., 2013; Riedel et al., 2010; 
Xiong et al., 2015; Vijayakumaran et al., 2015). SUMOylation of Hsp90 has been shown to 
inhibit the interaction with the Aha1 co-chaperone (Mollapour et al., 2014). Therefore, inhibiting 
Hsp90 SUMOylation could result in an effective downregulation of Hsp90 activity and 
consequently an increase in macroautophagy. The current data does not provide a direct link 
between inhibiting Hsp90 SUMOylation and the increased macroautophagy observed. However, 
both GA and AA treatments resulted in similar increases in macroautophagy and reduction in 
SUMO-1 90 KDa conjugates. The SUMO pathway could influence autophagy via multiple 
factors. Indeed, SUMOylation of Vps34, which forms part of the autophagosome machinery, 
also has the potential to modulate macroautophagy (Yang et al., 2013). Moreover, Cuervo and 
co-workers have proposed that synergy between macroautophagy and CMA is crucial in PD 
(Cuervo and Wong, 2014). Thus, inhibiting the SUMOylation of lysosomal Hsp90, which occurs 
in response to protein aggregates, may be able to affect the balance between CMA and 
macroautophagy. Inhibiting Hsp90 activity could also influence autophagosome formation via 
the mTor signalling pathway. Conversely, promoting clearance of -syn aggregates would in 
itself also result in reduced Hsp90 and reduced Hsp90-SUMO-1 conjugate. 
 
We investigated LC3 as a marker of autophagosomes in -syn aggregate positive and GA and 
AA treated cells. Western blot analysis showed that LC3b, an indicator of macroautophagic 
activity, showed no significant changes in cellular levels when comparing aggregate-positive 
cells to controls in post-treated cells. This was consistent with the results obtained with 
immunofluorescence staining of cells, where there were no significant changes in levels of LC3- 
positive puncta. However, when cells were subjected to GA treatments, Western blot analysis 
showed a significant increase in LC3b. Parallel results were observed in cells immunostained for 
LC3, showing an increase in LC3-positive puncta in aggregate-bearing cells treated with GA. 
Furthermore, the observed puncta were much larger than those found in control cells. These 
results indicate that GA/AA may cause an upregulation of macroautophagy. Previous studies 




syn mutants are not able to be degraded by CMA, binding to the LAMP2A pore and inhibiting 
lysosomal degradation (Cuervo et al., 2004). Thus, promoting macroautophagy may overcome 
the block to CMA in response to -syn aggregates, resulting in clearance of -syn aggregates. 
 
The current study investigated -syn aggregates in KCl-depolarised cells treated with GA (and 
AA) to determine if these reagents could affect the frequency of -syn aggregates. 
Immunofluorescence of aggregate positive cells compared to those treated with increasing 
concentrations of GA showed a significant and progressive decrease in -syn-positive 
aggregates. Large aggregates (2m) that were observed in aggregate positive cells with no GA 
treatment resembled the Lewy body IBs observed in neuropathological tissue. However, these 
large aggregates were greatly diminished when treated with GA, with some small aggregates 
(<2m) being present at low GA concentration and an almost total absence of microscopically- 
visible aggregates at higher GA concentrations. 
 
The upregulation of LC3 puncta observed in depolarised cells treated with GA suggests that cells 
upregulated the level of autophagosomes. This indicates that cells treated with GA activate 
macroautophagy thereby mediating -syn aggregate clearance, that may overcome the block to 
CMA-mediated -syn degradation caused by the binding of -syn aggregates to autophagy 
components. This was confirmed by experiments that showed that blocking autophagy also 
blocked aggregate clearance, but did not suppress the GA-mediated increase in frequency of 
autophagosomes. Moreover, this finding indicates that the activation of macroautophagy by GA 
may be beneficial in protecting neural cells against toxic stress due to the accumulation of -syn 
aggregates. Thus, GA may stimulate -syn aggregate clearance by upregulating macroautophagy 
and could represent a new therapeutic target in PD. Further studies will be required to better 
elucidate the mechanism of GA in promoting autophagy; whether this is dependent on the 
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Figure 1. Ginkgolic acid and anacardic acid yield reduced -syn aggregates. (A) 
Comparison of control SH-SY5Y to 50mM KCl depolarized SH-SY5Y (24 h). 
Immunofluorescence showed increased -syn puncta in KCl depolarised SH-SY5Y (green). 
(Scale bar, 20m). (B) Immunofluorescence staining comparing depolarized SH-SY5Y to AA 
treated, depolarized SH-SY5Y. (C) Cell counting analysis of AA treatments of depolarized and 
non-depolarised SH-SY5Y indicating a significant decrease in -syn positive aggregates in AA- 
treated cells. (D) Immunofluorescence staining of depolarized control SH-SY5Y compared to 
GA treated, depolarized SH-SY5Y. (Scale bar, 10m). (E) Cell counting analysis of GA 
treatments of depolarized and non-depolarised SH-SY5Y show a significant decrease in -syn 
positive aggregates in SH-SY5Y in GA-treated cells. (F), (G) SUMO-1-immunofluoescence of 
depolarized SH-SY5Y cells for controls and AA- or GA-treatments (24 h). Arrows indicate 
yellow puncta and inclusion bodies from co-localised SUMO-1 (red) to lysosomes (Cathepsin D; 
green). (Scale bar, 20m). (B)Error bars indicate SEM. * = p, 0.05; ** = p, 0.01; *** = p, 0.001; 
**** = p, 0.0001. 
 
Figure 2. Rat cortical primary neurons show reduced -syn aggregates upon ginkgolic acid 
treatment. (A-C) Representative images of 7 DIV primary neurons treated with 0, 25 mM or 50 
mM KCl for 1 h, then incubated for 48 h. (D-F) Representative images of co-treatments with 
10M GA. Red, MAP2. Green, -syn. Blue, DAPI. 
 
Figure 3. Ginkgolic acid treatment has little effect on SUMO-1 conjugates. (A)Western blot 
showing SUMO-1 bands of depolarized and non-depolarised SH-SY5Y under increasing 
concentrations of GA at 10M, 40M, 80M. (B) Western blot analysis of SUMO-1 with GA 
treatments in depolarized and non-depolarised SH-SY5Yshowing a significant decrease in 
SUMO-1 band intensity at 40M and 80M GA only for the 90 KDa band that increased upon 
KCl depolarization. (C) Western blot for Hsp90 with different GA treatment concentrations. (D) 
Western blot analysis showed a significant increase after KCl depolarisation and a significant 
decrease at 80M GA in depolarized SH-SY5Y cell lysates. Error bars indicate the SEM. * = p, 




Figure 4. Frequency of LC3-positive autophagosomes increases with GA and AA 
treatment in depolarized and non-depolarised SH-SY5Y. (A), (C) Immunofluorescence (24 
h) showing LC3-positive puncta (red) in depolarized SH-SY5Y show significant increases in 
LC3 puncta upon GA and AA treatments. (Scale bar, 20m). (B), (D) Cell counting analysis of 
LC3-positive autophagosome levels with GA and AA in depolarized and non-depolarized SH- 
SY5Y indicate a significant upregulation of the frequency of LC3-positve autophagosomes. (E) 
Representative Western blot (48 h) illustrating the LC3a (15kDa) and LC3b (10kDa) bands at 
increasing concentrations of GA in depolarized and non-depolarized SH-SY5Y, showing 
increased intensity of the LC3b band at concentrations of GA at 40M and 80M. (F) 
Integration of LC3b in depolarized and non-depolarized SH-SY5Y at increasing concentrations 
of GA indicate a significant increase in LC3b in non-depolarised SHSY5Y at 40M and 80M 
GA and at 80M GA in depolarised SH-SY5Y. (G) 7 DIV Rat cortical primary neurons 
subjected to 10M GA, with or without KCl depolarization, showing increased LC3-positive 
autophagosomes (arrowheads). Blue, DAPI. Red, SUMO-1. Lilac, LC3. Green, -syn. Error bars 
indicate SEM. * = p, 0.05; ** = p, 0.01; *** = p, 0.001; **** = p, 0.0001. 
Figure 5. Reduced frequency of -syn-positive aggregates in depolarised SH-SY5Y cells 
subjected to GA post-treatment. (A) Immunofluorescence of SH-SY5Y subjected to KCl- 
depolarisation and incubation for 48 h where the presence of large and small Lewy-body-like - 
syn-positive aggregates in cells was observed in KCl depolarised SH-SY5Y (arrows). (Inset) Co- 
labelling revealed frequent cytosolic SUMO puncta in -syn-positive cells (arrowhead) (Scale 
bar, 10m). (B) SH-SY5Y subjected to post-treatments of GA at various concentrations 
indicating large and small -syn aggregates in SH-SY5Y cells (arrows) where there is a decrease 
in the frequency of -syn positive cells at 10M treatments of GA and only small and less 
frequent -syn-positive aggregates in cells subjected to higher concentrations of GA at 40M 
and 80M. (Scale bar, 10m). (C) Cell counting analysis of the proportion of aggregate-bearing 
non-depolarised and depolarised SH-SY5Y. There were no large aggregates present in cells of 
non-depolarised SH-SY5Y. The percentage of aggregate-bearing cells in KCl depolarised SH- 
SY5Y increased significantly when compared to control. The percentage of aggregate-bearing 
cells were significantly decreased at 10M, 40M and 80M GA treatments. (D) MTT cell 




incubation, treated with increasing concentrations of GA at 24 h post depolarization. Error bars 
indicate SEM. * = p, 0.05; ** = p, 0.01; *** = p, 0.001; **** = p, 0.0001. 
 
 
Figure 6. SUMO-1 conjugates in SH-SY5Y cells after post-depolarisation treatment with 
GA. (A) Western blot illustrating SUMO-1 bands comparing cell lysates subjected to increasing 
concentrations of GA at 10M, 40M and 80M in depolarised and non-depolarised SH-SY5Y. 
(B) Integrated SUMO-1-conjugate band intensity at various concentrations of GA in depolarised 
and non-depolarised SH-SY5Y cell lysates indicating a significant increase in the integrated 
SUMO-1 bands when treated with KCl. GA treatments at 40M and 80M GA show a decrease 
in the integrated SUMO-1 only for the 90KDa band in depolarised SH-SY5Y. (C) Western blot 
of Hsp 90 in depolarised and non-depolarised SH-SY5Ycell lysates subjected to increasing 
concentrations of GA. (D) Integration of the Hsp 90 band shows a significant decrease in the 
intensity at 40M and 80M GA treatments in depolarised SH-SY5Y. Error bars indicate SEM. 
* = p, 0.05; ** = p, 0.01; *** = p, 0.001; **** = p, 0.0001. 
 
 
Figure 7. Increased LC3-positive autophagosomes and LC3b expression in GA post-treated 
depolarised and non-depolarised SH-SY5Y cells. (A) Immunofluorescence representative 
images of GA treated depolarised and non-depolarised SH-SY5Y showing LC3-positive 
autophagosome puncta (red) show upregulation in LC3-positive puncta (red) in non-depolarised 
and depolarised SH-SY5Y. (Scale bar, 10m). (B) Western blot illustrating LC3a (15 kDa) and 
LC3b (10kDa) bands of depolarised and non-depolarised SH-SY5Y cell lysates subjected to 
various concentrations of GA post-treatment. (C) Western blot analysis comparing LC3b band 
intensity of depolarised and non-depolarised SH-SY5Y subjected to various post-treatments with 
GA indicating a significant upregulation of LC3b ratio in cell lysates subjected to 80M GA. 
Error bars indicate SEM. * = p, 0.05; ** = p, 0.01; *** = p, 0.001; **** = p, 0.0001. 
 
Figure 8. Autophagy inhibitors block -syn aggregate clearance in post-GA-treated KCl- 
depolarized SH-SY5Y cells. (A-F) Bafilomycein A1 or chloroquine pre-treatment (24 hr post- 
KCL-depolarization) results in no significant differences in aggregate frequency with or without 




significant effect in LC3-positive autophagosome frequency in GA-treated KCl-depolarized 
cells. Scale bars, 20 µM. Error bars indicate SEM. * = p, 0.05; ** = p, 0.01; *** = p, 0.001; **** 
= p, 0.0001. 
 
 
Supplementary Figure 1. (A) Cell counting analysis of SUMO-1 positive lysosomes with AA 
or GA treatments in non-depolarised and depolarized SH-SY5Y, showing a significant decrease 
in the percentage of SUMO-1 positive lysosomes is observed in depolarised SH-SY5Y treated 
with AA or GA. (B) Western blot analysis comparing the integration of SUMO-1 bands in both 
non-depolarised and depolarized SH-SY5Y with GA treatments (48 h), indicating a significant 
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